Paper Diagnostics Market

Market Outlook for Paper Diagnostics

As per the latest industry analysis published by Fact.MR, global market for paper diagnostics is likely to be valued at US$ 7.2 Bn in 2021, and is slated to accelerate at a CAGR of 8.1% across the 2021-2031 forecast period, reflecting more than 2x increase. Paper-based lateral flow assays are projected to be most demanded, accumulating over 60% revenue until 2031.

Key Points Covered in Paper Diagnostics Industry Survey

• Market Estimates and Forecasts 2016-2031
• Key drivers and restraints shaping market growth
• Segment-wise, Country-wise, and Region-wise Analysis
• Competition Mapping and Benchmarking
• Market Share Analysis
• Key Product Innovations and Regulatory Climate
• COVID-19 Impact on Paper Diagnostics Market and How to Navigate
• Recommendation and Key Winning Strategy

Sales Analysis of Paper Diagnostics 2016-2020 Vs Future Outlook 2021-2031

Historically, the global paper diagnostics market flourished at a robust rate of nearly 7% CAGR from 2016 to 2020. Rapid advancements in diagnostic approaches, including a shift towards low cost diagnosis, has been one of the key influencing factors impacting demand.

The COVID-19 pandemic further opened new avenues for the paper diagnostics industry expansion. With substantial limitations associated with mainstream diagnostic approaches (RT-PCR, ELISA and RT-LAMP), clinicians have been adopting paper diagnostics for understanding viral genome sequence and better understand its spread.

Soaring R&D investments and increasing government stimulus to the healthcare sector is expected to surge in the forecast period. The market worth is projected to reach US$ 15.7 Bn, following a CAGR of 8.1% during the 2021-2031 assessment period. Furthermore, growing cases of cancer and advanced healthcare infrastructure in North America will enhance paper diagnostics prospects in the upcoming decade.

Increasing Cases of Autoimmune Diseases Bolstering Growth

Rising cases of autoimmune diseases and cancers coupled with the growing awareness among solutions available for fast and prompt diagnosis have resulted in high demand for the early detection of these diseases. According to the recent report of National Institutes of Health (NIH) published in April, 2020, the prevalence of autoimmune diseases in the United States was 11.0% for 1988-1991 and it had been increasing steadily to reach at 11.5% during 1999-2004 and at 15.9% during 2011-2012.

Paper diagnostics provide promising solutions for early diagnosis of these diseases while emphasizing on the key aspects of the diagnosis procedure and outcomes such as affordability, sustainability, portability, disposability, and others. According to the National Health and Nutrition Examination Survey (NHANES) of NIH, the rate of auto-immune diseases is forecast to grow further in the United States in the coming years. The data indicates that demand for paper diagnostics will surge considerably in the coming years

Technological Advancements to Open More Opportunistic Doors?

Advances in printed electronics provide a fitting foundation for implementing augmented functionality, while maintaining the affordability and disposability of paper-based diagnostics. Introduction of the technologically advanced paper-based sensor, 3D wax printing methods have potential advantages over conventional technologies, correlated benefits such as user-friendliness disposable nature, and low cost of fabrication are the factors associating towards the growth of this industry.

Currently, paper-based sensors are focused on microfluidic delivery of solution to the detection site whereas more advanced designs involve complex 3-D geometries based on the same microfluidic principles. Moreover, increasing investments by government organizations in R&D pertaining to development of novel in vitro diagnostics tests and devices have been providing an upthrust to the market. For instance, European Diagnostic Manufacturers Association (EDMA), which focuses on development and overall growth of the in vitro diagnostic industry in Europe, invests approximately € 1 billion in R&D of in vitro diagnostics every year.

Country-wise Analysis

How is Cancer Diagnostics Pushing Demand for Paper Diagnostics in the U.S?

The U.S is the epicentre for paper diagnostics in the world due to the burgeoning number of cancer cases and progressive healthcare infrastructure. According to the National Cancer Institute, the U.S. is likely to have 1,806,590 new cases of cancer in 2020 and nearly 606,520 people might succumb to the disease.

The demand for early and effective detection of cancer has therefore become a priority for the healthcare industry in North America. This in turn is boosting the demand for paper diagnostics in the region. According to Fact.MR, the country is expected to surge at over 8% CAGR.

The U.S has some of the world’s R&D facilities allowing it to offer some of the most cutting-edge items to the clients. For instance, a group of engineers from the Massachusetts Institute of Technology (MIT) have developed an inexpensive paper-based test which could improve cancer diagnosis rates based on urine samples by analysing biomarkers.

How is the Prevention of Infectious Diseases Outbreaks Driving Adoption in China?

According to fact.MR, China is likely to generate high prospects for the paper diagnostics industry, registering a CAGR of 6.6% during the forecast period.

High burden of chronic and infectious diseases, including diabetes, cancer, and COVID-19, is slated to significantly propel growth, as these chronic disorders can be diagnosed and monitored using paper diagnostic products.

According to the World Health Organization (WHO), 102,762 COVID-19 cases were recorded as of March 2021, with 4,851 deaths in China. The increasing burden of the COVID-19 pandemic will lead to a high requirement of tests, which will boost the paper diagnostics market in the country.

Category-wise Insights

Why Lateral Flow Assays are experiencing an Incline in the Industry? 

Currently, lateral flow assays are the leading segment in terms of product type in the global market for paper diagnostics. This segment will likely account for over 60% revenue until 2031. Growth can be attributed to extensive usage rate as pregnancy tests.

Besides, mounting incidence of infectious diseases such as HIV, TB, and pneumonia is assessed to spur the growth of the segment during the forecast period. Lateral flow assay (LFA) has made a paradigm shift in the in vitro diagnosis field due to its rapid turnaround time, ease of operation and exceptional affordability. Currently used LFAs predominantly use antibodies. 

How did COVID-19 Spur Paper Diagnostics across Hospitals & Clinics?

In terms of end-user, hospitals and clinics are the foremost utilizers of paper diagnostics. With the increase in awareness among doctors, other healthcare staff, and patients, the demand for paper diagnostics solutions is rising. Fact.MR expects the segment to experience a CAGR of 7% until 2031.

During the height of the coronavirus pandemic, documented limitations associated with rapid diagnostic approaches such as RT-PCR (real-time PCR), RT-LAMP and ELISA prompted high reliance on paper-based diagnostics, capable of testing viral genome sequence to reflect information on the spread and distribution of the pathogen, especially in wastewater.

Competitive Landscape

Prominent players are embracing innovative approaches such as ground-breaking marketing tactics, enhanced R&D investments, technological advancements and mergers.

• The Wyss Institute has developed paper-based synthetic gene networks as a next generation diagnostic technology for use in global healthcare crises and patient-care. This new type pf platform may also provide patients and consumers with simple-to-use texts for a variety of other health problems.
• In Sept 2017, U.S. ARKRAY, Inc. (ARKRAY) launched the ADAMS™ A1c HA-8180V System for haemoglobin A1c testing. The system obtained FDA 510(k) clearance as an aid in the monitoring and diagnosis of individuals with diabetes. This fully automated analyser utilizes gold standard HPLC technology.

Report Scope

Attribute	Details
Market size value in 2020	USD 7.2 Billion
Market forecast value in 2031	USD 15.7 Billion
Growth Rate	CAGR of 8.1% (2021-2031)
Forecast Period	2021-2031
Historical Data Available for	2016-2020
Market Analysis	US$ Mn for Value
Key Regions Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Covered	U.S. Canada Germany U.K. France Spain Italy Russia China Japan South Korea India Thailand Indonesia Malaysia Australia New Zealand Brazil Mexico Argentina GCC South Africa
Key Market Segments Covered	Product End User Region
Key Companies Profiled	Abcam Plc. Acon Laboratories Inc. Bio-Rad Laboratories Inc. Siemens Healthineers Chembio Diagnostic Systems Inc. Arkray Inc. Cytodiagnostics Inc.
Pricing	Available upon Request

Key Segments Covered

• Product

  • Paper-based Lateral Flow Assays
  • Paper-based Dipsticks
  • Paper-based Micro Fluidics

• End User

  • Paper Diagnostics for Hospitals & Clinics
  • Paper Diagnostics for Home Care Settings